These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33095521)

  • 1. Lupus Anticoagulant in Patients with Covid-19.
    Gooding R; Myers B; Salta S
    N Engl J Med; 2020 Nov; 383(19):1893. PubMed ID: 33095521
    [No Abstract]   [Full Text] [Related]  

  • 2. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19.
    Bowles L; Platton S; Yartey N; Dave M; Lee K; Hart DP; MacDonald V; Green L; Sivapalaratnam S; Pasi KJ; MacCallum P
    N Engl J Med; 2020 Jul; 383(3):288-290. PubMed ID: 32369280
    [No Abstract]   [Full Text] [Related]  

  • 3. Lupus anticoagulant is frequent in patients with Covid-19.
    Harzallah I; Debliquis A; Drénou B
    J Thromb Haemost; 2020 Aug; 18(8):2064-2065. PubMed ID: 32324958
    [No Abstract]   [Full Text] [Related]  

  • 4. Lupus Anticoagulant in Patients with Covid-19. Reply.
    Platton S; Bowles L; Pasi KJ
    N Engl J Med; 2020 Nov; 383(19):1893-1894. PubMed ID: 33095522
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to "Lupus anticoagulant is frequent in patients with Covid-19" (JTH-2020-00483).
    Tang N
    J Thromb Haemost; 2020 Aug; 18(8):2065-2066. PubMed ID: 32379935
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute Ischemic Stroke in a Lupus Anticoagulant-Positive Woman With COVID-19.
    Gemcioglu E; Erden A; Davutoglu M; Karabuga B; Kucuksahin O
    J Clin Rheumatol; 2020 Sep; 26(6):236-237. PubMed ID: 32694351
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessment of Lupus Anticoagulant Positivity in Patients With Coronavirus Disease 2019 (COVID-19).
    Reyes Gil M; Barouqa M; Szymanski J; Gonzalez-Lugo JD; Rahman S; Billett HH
    JAMA Netw Open; 2020 Aug; 3(8):e2017539. PubMed ID: 32785632
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19 and ischemic stroke: Should we systematically look for lupus anticoagulant and antiphospholipid antibodies?
    Aubignat M; Godefroy O
    Rev Neurol (Paris); 2020 Jun; 176(6):505-506. PubMed ID: 32409176
    [No Abstract]   [Full Text] [Related]  

  • 9. The association between D-dimers in COVID-19 patients and mortality remains beset of uncertainties.
    Gris JC; Loubet P; Roger C; Cochery-Nouvellon E; Mauboussin JM; Muller L; Bouvier S; Laureillard D; Barbar SD; Mercier É; Lefrant JY; Sotto A
    J Thromb Haemost; 2020 Aug; 18(8):2068-2070. PubMed ID: 32495985
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism.
    Galeano-Valle F; Oblitas CM; Ferreiro-Mazón MM; Alonso-Muñoz J; Del Toro-Cervera J; di Natale M; Demelo-Rodríguez P
    Thromb Res; 2020 Aug; 192():113-115. PubMed ID: 32425261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 31-Year-Old Man with COVID-19-Associated Empyema and Lupus Anticoagulant.
    Yarlagadda K; Mi K; Sendil S; Koons CL; Komanduri S; Cinicola JT
    Am J Case Rep; 2020 Aug; 21():e926623. PubMed ID: 32807764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology.
    Mantovani Cardoso E; Hundal J; Feterman D; Magaldi J
    Clin Rheumatol; 2020 Sep; 39(9):2811-2815. PubMed ID: 32720260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombocytopenia and coagulation disorders due to COVID 19 infection with concomitant cardiovascular diseases requiring anti-platelet and anticoagulant therapy, which strategy?
    Buioni D; Nardi P; Ruvolo G
    Clin Chim Acta; 2020 Sep; 508():109. PubMed ID: 32417209
    [No Abstract]   [Full Text] [Related]  

  • 14. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy.
    Belen-Apak FB; Sarıalioğlu F
    J Thromb Thrombolysis; 2020 Aug; 50(2):278-280. PubMed ID: 32372336
    [No Abstract]   [Full Text] [Related]  

  • 15. The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19.
    Canonico ME; Siciliano R; Scudiero F; Sanna GD; Parodi G
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):262-264. PubMed ID: 32383737
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy".
    Coto-Hernández R; Fábregas Ruano MT
    J Thromb Haemost; 2020 Jun; 18(6):1519-1520. PubMed ID: 32302445
    [No Abstract]   [Full Text] [Related]  

  • 17. Immune-Mediated Coagulopathy in COVID-19 Infection.
    Vadasz Z; Brenner B; Toubi E
    Semin Thromb Hemost; 2020 Oct; 46(7):838-840. PubMed ID: 32877959
    [No Abstract]   [Full Text] [Related]  

  • 18. Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.
    Menezes-Rodrigues FS; Padrão Tavares JG; Pires de Oliveira M; Guzella de Carvalho R; Ruggero Errante P; Omar Taha M; José Fagundes D; Caricati-Neto A
    J Thromb Haemost; 2020 Aug; 18(8):2073-2075. PubMed ID: 32408391
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to 'Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy'.
    Tang N
    J Thromb Haemost; 2020 Jun; 18(6):1520-1521. PubMed ID: 32302451
    [No Abstract]   [Full Text] [Related]  

  • 20. In Response to "Coagulopathy of Coronavirus Disease 2019".
    Ng J; Fan BE; Chia YW
    Crit Care Med; 2020 Nov; 48(11):e1159-e1160. PubMed ID: 32897666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.